Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Diabetes Reports
Published in: Current Diabetes Reports 6/2015

Open Access 01-06-2015 | Pathogenesis of Type 2 Diabetes and Insulin Resistance (RM Watanabe, Section Editor)

β Cell Dysfunction Versus Insulin Resistance in the Pathogenesis of Type 2 Diabetes in East Asians

Authors: Daisuke Yabe, Yutaka Seino, Mitsuo Fukushima, Susumu Seino

Published in: Current Diabetes Reports | Issue 6/2015

Login to get access

Abstract

Type 2 diabetes (T2DM) is one of the most serious global health problems and is mainly a result of the drastic increase in East Asia, which includes over a fourth of the global diabetes population. Lifestyle factors and ethnicity are two determinants in the etiology of T2DM, and lifestyle changes such as higher fat intake and less physical activity link readily to T2DM in East Asians. It is widely recognized that T2DM in East Asians is characterized primarily by β cell dysfunction, which is evident immediately after ingestion of glucose or meal, and less adiposity compared to the disease in Caucasians. These pathophysiological differences have an important impact on therapeutic approaches. Here, we revisit the pathogenesis of T2DM in light of β cell dysfunction versus insulin resistance in East Asians and discuss ethnic differences in the contributions of insulin secretion and insulin resistance, together with incretin secretin and action, to glucose intolerance.
Literature
1.
IDF Diabetes Atlas 2014 Update Sixth Edition. Brussels: International Diabetes Federation; 2014.
2.
Yoon KH, Lee JH, Kim JW, Cho JH, Choi YH, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006;368:1681–8.CrossRefPubMed
3.
Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009;301:2129–40.CrossRefPubMed
4.
Abate N, Chandalia M. The impact of ethnicity on type 2 diabetes. J Diabet Complicat. 2003;17:39–58.CrossRef
5.••
Ntuk UE, Gill JM, Mackay DF, Sattar N, Pell JP. Ethnic-specific obesity cutoffs for diabetes risk: cross-sectional study of 490,288 UK Biobank participants. Diabetes Care. 2014;37:2500–7. An original article clarifying that East Asians develop type 2 diabetes at lower body mass index compared to Caucasians through a large multi-ethnic cohort in the UK.CrossRefPubMed
6.
Nakanishi S, Okubo M, Yoneda M, Jitsuiki K, Yamane K, et al. A comparison between Japanese-Americans living in Hawaii and Los Angeles and native Japanese: the impact of lifestyle westernization on diabetes mellitus. Biomed Pharmacother. 2004;58:571–7.CrossRefPubMed
7.•
Fujimoto WY, Boyko EJ, Hayashi T, Kahn SE, Leonetti DL, et al. Risk factors for type 2 diabetes: lessons learned from Japanese Americans in Seattle. J Diabetes Investig. 2012;3:212–24. An important review describing characteristics of Japanese American’s diabetes which is highly relevant to discuss pathogenesis of type 2 diabetes among East Asians.CrossRefPubMedCentralPubMed
8.•
Moller JB, Dalla Man C, Overgaard RV, Ingwersen SH, Tornoe CW, et al. Ethnic differences in insulin sensitivity, beta-cell function, and hepatic extraction between Japanese and Caucasians: a minimal model analysis. J Clin Endocrinol Metab. 2014;99:4273–80. An original article describing direct comparisons of insulin secretion and resistance, during intravenous glucose tolerance test, between Japanese and Caucasians.CrossRefPubMed
9.•
Moller JB, Pedersen M, Tanaka H, Ohsugi M, Overgaard RV, et al. Body composition is the main determinant for the difference in type 2 diabetes pathophysiology between Japanese and Caucasians. Diabetes Care. 2014;37:796–804. An original article describing direct comparisons of insulin secretion and resistance, during oral glucose tolerance test, between Japanese and Caucasians.CrossRefPubMed
10.
Fukushima M, Suzuki H, Seino Y. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract. 2004;66S:S37–44.CrossRef
11.
12.
Kagan A, Harris BR, Winkelstein Jr W, Johnson KG, Kato H, et al. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: demographic, physical, dietary and biochemical characteristics. J Chron Dis. 1974;27:345–64.CrossRefPubMed
13.
West KM. Diabetes in American Indians and other native populations of the New World. Diabetes. 1974;23:841–55.CrossRefPubMed
14.
Olefsky JM. LIlly lecture 1980. Insulin resistance and insulin action. An in vitro and in vivo perspective. Diabetes. 1981;30:148–62.CrossRefPubMed
15.
McNeely MJ, Boyko EJ. Type 2 diabetes prevalence in Asian Americans: results of a national health survey. Diabetes Care. 2004;27:66–9.CrossRefPubMed
16.
Fujimoto WY, Hershon K, Kinyoun J, Stolov W, Weinberg C, et al. Type II diabetes mellitus in Seattle and Tokyo. Tohoku J Exp Med. 1983;141(Suppl):133–9.CrossRefPubMed
17.
Lyssenko V, Almgren P, Anevski D, Perfekt R, Lahti K, et al. Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. Diabetes. 2005;54:166–74.CrossRefPubMed
18.
Ogihara T, Mirmira RG. An islet in distress: beta cell failure in type 2 diabetes. J Diabetes Investig. 2010;1:123–33.PubMedCentralPubMed
19.
20.
Fukushima M, Usami M, Ikeda M, Nakai Y, Taniguchi A, et al. Insulin secretion and insulin sensitivity at different stages of glucose tolerance: a cross-sectional study of Japanese type 2 diabetes. Metabolism. 2004;53:831–5.CrossRefPubMed
21.
Kadowaki T, Miyake Y, Hagura R, Akanuma Y, Kajinuma H, et al. Risk factors for worsening to diabetes in subjects with impaired glucose tolerance. Diabetologia. 1984;26:44–9.CrossRefPubMed
22.
Iwahashi H, Okauchi Y, Ryo M, Noguchi M, Morita S, et al. Insulin-secretion capacity in normal glucose tolerance, impaired glucose tolerance, and diabetes in obese and non-obese Japanese patients. J Diabetes Investig. 2012;3:271–5.CrossRefPubMedCentralPubMed
23.
Yabe D, Kuroe A, Watanabe K, Iwasaki M, Hamasaki A, et al. Early phase glucagon and insulin secretory abnormalities, but not incretin secretion, are similarly responsible for hyperglycemia after ingestion of nutrients. J Diabet Complicat. 2015;29(3):413–21.
24.
Seino Y, Taminato T, Goto Y, Ikeda M, Imura H. Comparative insulinogenic effect of glucose, arginine and glucagon in patients with diabetes mellitus, endocrine disorders and liver disease. Acta Diabetol. 1975;12(2):89–99.CrossRef
25.
Kosaka K, Kuzuya T, Akanuma Y, Hagura R. Increase in insulin response after treatment of overt maturity-onset diabetes is independent of the mode of treatment. Diabetologia. 1980;18:23–8.CrossRefPubMed
26.
Seino Y, Goto Y, Kurahachi H, Sakurai H, Ikeda M. Alteration of plasma glucagon response to arginine after treatment in patients with diabetes mellitus, Cushing’s syndrome and hypothyroidism. Horm Metab Res. 1977;9:28–32.CrossRefPubMed
27.
Seino Y, Ikeda M, Kurahachi H, Taminato T, Sakurai H, et al. Failure of suppress plasma glucagon concentrations by orally administered glucose in diabetic patients after treatment. Diabetes. 1978;27:1145–50.CrossRefPubMed
28.
Tripathy D, Carlsson M, Almgren P, Isomaa B, Taskinen MR, et al. Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study. Diabetes. 2000;49:975–80.CrossRefPubMed
29.
Kim DJ, Lee MS, Kim KW, Lee MK. Insulin secretory dysfunction and insulin resistance in the pathogenesis of Korean type 2 diabetes mellitus. Metabolism. 2001;50:590–3.CrossRefPubMed
30.
Choi YH, Ahn YB, Yoon KH, Kang MI, Cha BY, et al. New ADA criteria in the Korean population: fasting blood glucose is not enough for diagnosis of mild diabetes especially in the elderly. Korean J Intern Med. 2000;15:211–7.CrossRefPubMed
31.
Qian L, Xu L, Wang X, Fu X, Gu Y, et al. Early insulin secretion failure leads to diabetes in Chinese subjects with impaired glucose regulation. Diabetes Metab Res Rev. 2009;25:144–9.CrossRefPubMed
32.
Pang C, Bao YQ, Wang C, Lu JX, Jia WP, et al. Relationship between the level of fasting plasma glucose and beta cell functions in Chinese with or without diabetes. Chin Med J (Engl). 2008;121:2119–23.
33.
Taniguchi A, Nakai Y, Fukushima M, Kawamura H, Imura H, et al. Pathogenic factors responsible for glucose intolerance in patients with NIDDM. Diabetes. 1992;41:1540–6.CrossRefPubMed
34.
Welch S, Gebhart SS, Bergman RN, Phillips LS. Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in diabetic subjects. J Clin Endocrinol Metab. 1990;71:1508–18.CrossRefPubMed
35.
Kodama K, Tojjar D, Yamada S, Toda K, Patel CJ, et al. Ethnic differences in the relationship between insulin sensitivity and insulin response: a systematic review and meta-analysis. Diabetes Care. 2013;36:1789–96.CrossRefPubMedCentralPubMed
36.
Tanaka S, Horimai C, Katsukawa F. Ethnic differences in abdominal visceral fat accumulation between Japanese, African-Americans, and Caucasians: a meta-analysis. Acta Diabetol. 2003;40 Suppl 1:S302–4.CrossRefPubMed
37.
DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group. Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. BMJ 1998;317:371–75.
38.
Qiao Q, Nakagami T, Tuomilehto J, Borch-Johnsen K, Balkau B, et al. Comparison of the fasting and the 2-h glucose criteria for diabetes in different Asian cohorts. Diabetologia. 2000;43:1470–5.CrossRefPubMed
39.
Suzuki H, Fukushima M, Usami M, Ikeda M, Taniguchi A, et al. Factors responsible for development from normal glucose tolerance to isolated postchallenge hyperglycemia. Diabetes Care. 2003;26:1211–5.CrossRefPubMed
40.
Mitsui R, Fukushima M, Taniguchi A, Nakai Y, Aoyama S, et al. Insulin secretory capacity and insulin sensitivity in impaired fasting glucose in Japanese. J Diabetes Investig. 2012;3:377–83.CrossRefPubMedCentralPubMed
41.
Nishi Y, Fukushima M, Suzuki H, Mitsui R, Ueda N, et al. Insulin secretion and insulin sensitivity in Japanese subjects with impaired fasting glucose and isolated fasting hyperglycemia. Diabetes Res Clin Pract. 2005;70:46–52.CrossRefPubMed
42.
Nakagami T, Qiao Q, Carstensen B, Nhr-Hansen C, Hu G, et al. Age, body mass index and type 2 diabetes-associations modified by ethnicity. Diabetologia. 2003;46:1063–70.CrossRefPubMed
43.
Fujimoto WY, Leonetti DL, Kinyoun JL, Shuman WP, Stolov WC, et al. Prevalence of complications among second-generation Japanese-American men with diabetes, impaired glucose tolerance, or normal glucose tolerance. Diabetes. 1987;36:730–9.CrossRefPubMed
44.
Fujimoto WY, Leonetti DL, Kinyoun JL, Newell-Morris L, Shuman WP, et al. Prevalence of diabetes mellitus and impaired glucose tolerance among second-generation Japanese-American men. Diabetes. 1987;36:721–9.CrossRefPubMed
45.
Matsubara T, Mita A, Minami K, Hosooka T, Kitazawa S, et al. PGRN is a key adipokine mediating high fat diet-induced insulin resistance and obesity through IL-6 in adipose tissue. Cell Metab. 2012;15:38–50.CrossRefPubMed
46.
Yasuda K, Miyake K, Horikawa Y, Hara K, Osawa H, et al. Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat Genet. 2008;40:1092–7.CrossRefPubMed
47.
Unoki H, Takahashi A, Kawaguchi T, Hara K, Horikoshi M, et al. SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations. Nat Genet. 2008;40:1098–102.CrossRefPubMed
48.
Ullrich S, Su J, Ranta F, Wittekindt OH, Ris F, et al. Effects of I(Ks) channel inhibitors in insulin-secreting INS-1 cells. Pflugers Arch. 2005;451:428–36.CrossRefPubMed
49.
Yamauchi T, Hara K, Maeda S, Yasuda K, Takahashi A, et al. A genome-wide association study in the Japanese population identifies susceptibility loci for type 2 diabetes at UBE2E2 and C2CD4A-C2CD4B. Nat Genet. 2010;42:864–8.CrossRefPubMed
50.
Kimura M, Hattori T, Matsuda Y, Yoshioka T, Sumi N, et al. cDNA cloning, characterization, and chromosome mapping of UBE2E2 encoding a human ubiquitin-conjugating E2 enzyme. Cytogenet Cell Genet. 1997;78:107–11.CrossRefPubMed
51.
Tsai FJ, Yang CF, Chen CC, Chuang LM, Lu CH, et al. A genome-wide association study identifies susceptibility variants for type 2 diabetes in Han Chinese. PLoS Genet. 2010;6:e1000847.CrossRefPubMedCentralPubMed
52.
53.
Wolosker H, Blackshaw S, Snyder SH. Serine racemase: a glial enzyme synthesizing D-serine to regulate glutamate-N-methyl-D-aspartate neurotransmission. Proc Natl Acad Sci U S A. 1999;96:13409–14.CrossRefPubMedCentralPubMed
54.
Gonoi T, Mizuno N, Inagaki N, Kuromi H, Seino Y, et al. Functional neuronal ionotropic glutamate receptors are expressed in the non-neuronal cell line MIN6. J Biol Chem. 1994;269:16989–92.PubMed
55.
Cho YS, Chen CH, Hu C, Long J, Ong RT, et al. Meta-analysis of genome-wide association studies identifies eight new loci for type 2 diabetes in East Asians. Nat Genet. 2012;44:67–72.CrossRef
56.
Hwang JY, Sim X, Wu Y, Liang J, Tabara Y, et al. Genome-wide association meta-analysis identifies novel variants associated with fasting plasma glucose in East Asians. Diabetes. 2015;64(1):291–8.
57.
58.
Southam L, Soranzo N, Montgomery SB, Frayling TM, McCarthy MI, et al. Is the thrifty genotype hypothesis supported by evidence based on confirmed type 2 diabetes- and obesity-susceptibility variants? Diabetologia. 2009;52:1846–51.CrossRefPubMedCentralPubMed
59.
Cho YS, Lee JY, Park KS, Nho CW. Genetics of type 2 diabetes in East Asian populations. Curr Diabetes Rep. 2012;12:686–96.CrossRef
60.
Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab. 1986;63:492–8.CrossRefPubMed
61.
Knop FK, Vilsboll T, Hojberg PV, Larsen S, Madsbad S, et al. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes. 2007;56:1951–9.CrossRefPubMed
62.
Bagger JI, Knop FK, Lund A, Vestergaard H, Holst JJ, et al. Impaired regulation of the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96:737–45.CrossRefPubMed
63.
Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Investig. 2010;1:9–23.
64.
Yabe D, Seino Y. Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and beta cell preservation. Prog Biophys Mol Biol. 2011;107:248–56.CrossRefPubMed
65.
66.•
Drucker DJ. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes. 2013;62:3316–23. A useful review of intra- and extrapancreatic actions of glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1, which is highly relevant to discuss efficacy and safety of incretin-based therapies in the management of type 2 diabetes.CrossRefPubMedCentralPubMed
67.
68.•
Calanna S, Christensen M, Holst JJ, Laferrere B, Gluud LL, et al. Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia. 2013;56:965–72. An important systematic review and meta-analysis comparing secretion of glucagon-like peptide-1 between subjects with type 2 diabetes and normal glucose-tolerance.CrossRefPubMedCentralPubMed
69.•
Calanna S, Christensen M, Holst JJ, Laferrere B, Gluud LL, et al. Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies. Diabetes Care. 2013;36:3346–52. An important systematic review and meta-analysis comparing secretion of glucose-dependent insulinotropic polypeptide between subjects with type 2 diabetes and normal glucose-tolerance.CrossRefPubMedCentralPubMed
70.
Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia. 2011;54(1):10–8.
71.
Yabe D, Kuroe A, Lee S, Watanabe K, Hyo T, et al. Little enhancement of meal-induced GLP-1 secretion in Japanese: comparison of type 2 diabetes and healthy controls. J Diabetes Investig. 2010;1:56–9.CrossRefPubMedCentralPubMed
72.
Kozawa J, Okita K, Imagawa A, Iwahashi H, Holst JJ, et al. Similar incretin secretion in obese and non-obese Japanese subjects with type 2 diabetes. Biochem Biophys Res Commun. 2010;393:410–3.CrossRefPubMed
73.
Lee S, Yabe D, Nohtomi K, Takada M, Morita R, et al. Intact glucagon-like peptide-1 levels are not decreased in Japanese patients with type 2 diabetes. Endocr J. 2010;57:119–26.CrossRefPubMed
74.
Oh TJ, Park KS, Cho YM. Correlation of the incretin effect with first- and second-phase insulin secretions in Koreans with various glucose tolerance statuses. Clin Endocrinol (Oxf). 2014. doi:10.​1111/​cen.​12623.
75.
Oh TJ, Kim MY, Shin JY, Lee JC, Kim S, et al. The incretin effect in Korean subjects with normal glucose tolerance or type 2 diabetes. Clin Endocrinol (Oxf). 2014;80:221–7.CrossRef
76.
Yabe D, Watanabe K, Sugawara K, Kuwata H, Kitamoto Y, et al. Comparison of incretin immunoassays with or without plasma extraction: incretin secretion in Japanese patients with type 2 diabetes. J Diabetes Investig. 2012;3:70–9.CrossRefPubMedCentralPubMed
77.
Vollmer K, Holst JJ, Baller B, Ellrichmann M, Nauck MA, et al. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes. 2008;57:678–87.CrossRefPubMed
78.
Vilsboll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia. 2002;45:1111–9.CrossRefPubMed
79.
Saxena R, Hivert MF, Langenberg C, Tanaka T, Pankow JS, et al. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet. 2010;42:142–8.CrossRefPubMedCentralPubMed
80.
Hamasaki A, Harada N, Muraoka A, Yamane S, Joo E, et al. Not glucose tolerance but obesity impairs the numerical incretin effect in Japanese subjects. Diabetologia. 2011;54:S217.
81.
Gheni G, Ogura M, Iwasaki M, Yokoi N, Minami K, et al. Glutamate acts as a key signal linking glucose metabolism to incretin/cAMP action to amplify insulin secretion. Cell Rep. 2014;9:661–73.CrossRefPubMed
82.
Park H, Park C, Kim Y, Rascati KL. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis. Ann Pharmacother. 2012;46:1453–69.CrossRefPubMed
83.•
Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, et al. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and Non-Asians: a systematic review and meta-analysis. Diabetologia. 2013;56:696–708. An important systematic review and meta-analysis comparing glucose-lowering effects of dipeptidyl-peptidase-4 inhibitors between Asians and non-Asians.CrossRefPubMed
84.•
Kim YG, Hahn S, Oh TJ, Park KS, Cho YM. Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis. Diabetes Obes Metab. 2014;16(10):900–9.An important systematic review and meta-analysis comparing glucose-lowering effects of glucagon-like peptide-1 between Asians and non-Asians.
85.
Kubota A, Matsuba I, Saito T, Nabe K, Seino Y. Secretory units of islets in transplantation index is a useful clinical marker to evaluate the efficacy of sitagliptin in treatment of type 2 diabetes mellitus. J Diabetes Investig. 2011;2:377–80.CrossRefPubMedCentralPubMed
86.
Seino Y, Rasmussen MF, Clauson P, Kaku K. The once-daily human glucagon-like peptide-1 analog, liraglutide, improves β-cell function in Japanese patients with type 2 diabetes. J Diabetes Investig. 2012;3:388–95.CrossRefPubMedCentralPubMed
87.••
Iwasaki M, Hoshian F, Tsuji T, Hirose N, Matsumoto T, et al. Predicting efficacy of DPP-4 inhibitors in patients with type 2 diabetes: association of HbA1c reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels. J Diabetes Investig. 2012;3:464–7. An original article identifying a novel interaction of dietary habits and HbA1c-lowering of dipeptidyl-peptidase-4 inhibitors.CrossRefPubMedCentralPubMed
88.
Senmaru T, Fukui M, Kobayashi K, Iwase H, Inada S, et al. Dipeptidyl-peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations. J Diabetes Investig. 2012;3:498–502.CrossRefPubMedCentralPubMed
89.
Yabe D, Kuwata H, Iwasaki M, Usui R, Kurose T, et al. Effects of fish or meat intake before and after rice on postprandial glucose excursions and incretin secretion in type 2 diabetes: meal sequence as a novel target in dietary therapies for diabetes. Diabetes. 2014;64:LB12.
90.
Kubota A, Yabe D, Kanamori A, Kuroe A, Takahashi N, et al. Factors influencing the durability of the glucose-lowering effect of sitagliptin combined with a sulfonylurea. J Diabetes Investig. 2014;5:445–8.CrossRefPubMedCentralPubMed
91.
Kanamori A, Matsuba I. Factors associated with reduced efficacy of sitagliptin therapy: analysis of 93 patients with type 2 diabetes treated for 1.5 years or longer. J Clin Med Res. 2013;5:217–21.PubMedCentralPubMed
92.
Yabe D, Kuwata H, Kaneko M, Ito C, Nishikino R, et al. Use of the Japanese health insurance claims database to assess the risk of acute pancreatitis in patients with diabetes: comparison of DPP-4 inhibitors with other oral antidiabetic drugs. Diabetes Obes Metab. 2015;17(4):430–34.
93.
Kohro T, Yamazaki T, Sato H, Harada K, Ohe K, et al. Trends in antidiabetic prescription patterns in Japan from 2005 to 2011. Int Heart J. 2013;54:93–7.CrossRefPubMed
94.
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577–96.CrossRefPubMed
95.
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–79.CrossRefPubMedCentralPubMed
96.•
Yabe D, Seino Y. Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: friend or foe? J Diabetes Investig. 2014;5:475–7. An article comparing incidence of severe hypoglycemia by dipeptidyl peptidase-4 inhibitors in Japan and the USA.CrossRefPubMedCentralPubMed
97.
Takahashi H, Shibasaki T, Park JH, Hidaka S, Takahashi T, et al. Role of Epac2A/Rap1 signaling in interplay between incretin and sulfonylurea in insulin secretion. Diabetes. 2015;64(4):1262–72.
98.
Shibasaki T, Takahashi T, Takahashi H, Seino S. Cooperation between cAMP signalling and sulfonylurea in insulin secretion. Diabetes Obes Metab. 2014;16 Suppl 1:118–25.CrossRefPubMed
99.
Takahashi T, Shibasaki T, Takahashi H, Sugawara K, Ono A, et al. Antidiabetic sulfonylureas and cAMP cooperatively activate Epac2A. Sci Signal. 2013;6:ra94.PubMed
100.
Mukai E, Fujimoto S, Sato H, Oneyama C, Kominato R, et al. Exendin-4 suppresses SRC activation and reactive oxygen species production in diabetic Goto-Kakizaki rat islets in an Epac-dependent manner. Diabetes. 2010;60:218–26.CrossRefPubMedCentralPubMed
Metadata
Title
β Cell Dysfunction Versus Insulin Resistance in the Pathogenesis of Type 2 Diabetes in East Asians
Authors
Daisuke Yabe
Yutaka Seino
Mitsuo Fukushima
Susumu Seino
Publication date
01-06-2015
Publisher
Springer US
Published in
Current Diabetes Reports / Issue 6/2015
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-015-0602-9

Other articles of this Issue 6/2015

Current Diabetes Reports 6/2015 Go to the issue

Pathogenesis of Type 2 Diabetes and Insulin Resistance (RM Watanabe, Section Editor)

Ambient Air Pollution: An Emerging Risk Factor for Diabetes Mellitus

Diabetes, Other Diseases, and New Complications: Emerging Associations (JJ Nolan, Section Editor)

Nonalcoholic Fatty Liver Disease and Type 2 Diabetes: Common Pathophysiologic Mechanisms

Pathogenesis of Type 2 Diabetes and Insulin Resistance (RM Watanabe, Section Editor)

Does Nutrient Sensing Determine How We “See” Food?

Pathogenesis of Type 2 Diabetes and Insulin Resistance (RM Watanabe, Section Editor)

The Forgotten Role of Glucose Effectiveness in the Regulation of Glucose Tolerance

Health Care Delivery Systems and Implementation in Diabetes (EB Morton-Eggleston, Section Editor)

Diabetes Self-Management Interventions for Adults with Type 2 Diabetes Living in Rural Areas: A Systematic Literature Review

Psychosocial Aspects (KK Hood and S Jaser, Section Editors)

Treating the Most Vulnerable and Costly in Diabetes
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits